Luca Santarelli's VectivBio buys out small Massachusetts biotech, redoubling focus on metabolic disease
Luca Santarelli moved quickly after spinning out VectivBio from Therachon, getting an IPO settled in less than two years. On Tuesday, he continued charging forward with a new buyout that will see VectivBio expand its pipeline significantly over the next year and a half.
VectivBio has acquired Comet Therapeutics for an undisclosed equity and cash sum, the biotech announced Tuesday, aiming to target a swath of rare metabolic diseases. The goal is to hit the ground running, Santarelli told Endpoints News, with four new programs expected to launch at once and plans to enter the clinic in 18 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.